Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile
Launched by GALDERMA R&D · Mar 9, 2023
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or non-pregnant, non-breastfeeding females, 22 years of age or older
- • Intent to receive treatment for augmentation and correction of retrusion in the chin region.
- Exclusion Criteria:
- • Known/previous allergy of hypersensitivity to any injectable hyaluronic acid (HA) gel or gram-positive bacterial proteins.
- • Known/previous allergy or hypersensitivity to local anesthetics, e.g., lidocaine or other amide-type anesthetics.
- • Previous or present multiple severe allergies or severe allergies, such as manifested by anaphylaxis or angioedema or family history of angioedema.
- • Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from the subnasale.
- • Any previous aesthetic procedures or implants
- • Presence of any disease or lesion near or on the area to be treated.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Coral Gables, Florida, United States
Alpharetta, Georgia, United States
Rockville, Maryland, United States
Westport, Connecticut, United States
Nashville, Tennessee, United States
Los Angeles, California, United States
Manhattan Beach, California, United States
Aventura, Florida, United States
Atlanta, Georgia, United States
Chestnut Hill, Massachusetts, United States
Pflugerville, Texas, United States
San Juan, , Puerto Rico
Patients applied
Trial Officials
Study Director
Study Director
Galderma R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials